Molecular Dx Company Biocartis ‘At Inflection Point’ As It Eyes Infectious Disease Market
Belgian developer of cancer diagnostics is building an infectious disease portfolio on the back of its new SARS-CoV-2 test and collaborations with Immunexpress and Endpoint Health.
You may also be interested in...
In this edition of Report Digest, UK-based reporter Barnaby Pickering talks about the prostate cancer diagnostics and minimally invasive treatments markets with analyst Phil Greenfield. The two discuss ongoing developments in both treatment and diagnosis, while exploring driving and limiting factors for both.
An ambitious five-year public-private partnership plans to tackle non-adherence to medicines by giving patients EU-wide access to regulator-approved digital drug information. One year in, progress has been made in creating an app that could do just this.
Approval for Boston Scientific’s TheraSphere offers further access to the therapy that, until now, has only been available under a humanitarian device exemption.